Higano, C. S.; Schellhammer, P. F.; Small, E. J.; Burch, P. A.; Nemunaitis, J.; Yuh, L.; Provost, N.; Frohlich, M. W. (Aug 2009). “Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer”. Cancer115 (16): 3670-3679. doi:10.1002/cncr.24429. PMID19536890.
nih.gov
pubmed.ncbi.nlm.nih.gov
Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, Redfern CH, Ferrari AC, Dreicer R, Sims RB, Xu Y, Frohlich MW, Schellhammer PF; IMPACT Study Investigators (2010). “Sipuleucel-T immunotherapy for castration-resistant prostate cancer”. N. Engl. J. Med.363 (5): 411-422. PMID20818862.
Higano, C. S.; Schellhammer, P. F.; Small, E. J.; Burch, P. A.; Nemunaitis, J.; Yuh, L.; Provost, N.; Frohlich, M. W. (Aug 2009). “Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer”. Cancer115 (16): 3670-3679. doi:10.1002/cncr.24429. PMID19536890.
